Stevanato Group Management
Management Kriterienprüfungen 1/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Franco Stevanato
Geschäftsführender
n/a
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | n/a |
| Amtszeit als Geschäftsführer | 1.9yrs |
| Eigentum des Geschäftsführers | n/a |
| Durchschnittliche Amtszeit des Managements | 1.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.1yrs |
Jüngste Management Updates
Recent updates
Narrativ-Update • May 08
STVN: Core Biologics Shift Will Support Future Earnings Power Despite Guidance Reset
Narrative Update Analysts have trimmed Stevanato Group's average price target to reflect the recent cuts to $19, $26, $28 and $32, with updated models indicating a fair value estimate of about $24.81. This is based on slightly lower margin assumptions, a modest adjustment to long term growth, a somewhat lower discount rate, and a higher expected future P/E multiple.Narrativ-Update • Apr 23
STVN: Core Biologics Shift Will Drive Future Earnings Power
Analysts have trimmed their Stevanato Group price targets by several dollars across the Street, now clustering in a $19 to $32 range, as they refresh models after Q4 results and factor in slightly lower long term margin, growth, and P/E assumptions, alongside shifting expectations for GLP-1 and core biologics revenue contributions. Analyst Commentary Recent research updates show analysts marking down their price targets but still drawing a clear line between near term noise and the longer term setup for Stevanato Group, especially around GLP-1 exposure and the broader biologics portfolio.
Narrativ-Update • Apr 09
STVN: Biologics And GLP-1 Exposure Will Support Future Upside Potential
Analysts have trimmed the Stevanato Group fair value estimate from $18.09 to $17.50 after a series of reduced Street price targets, citing updated models post Q4 results, a higher discount rate, slightly softer revenue growth and margin assumptions, and a higher future P/E multiple that still reflects support for the core biologics and GLP-1 exposure. Analyst Commentary Recent Street research has largely centered on resetting expectations after Q4, with several bearish analysts trimming price targets while still recognizing the support from biologics and GLP-1 exposure.
Narrativ-Update • Mar 26
STVN: Biologics Focus And On Body Delivery Collaboration Will Drive Future Cash Flows
Analyst price targets for Stevanato Group have been reduced across several firms, with cuts ranging from $5.50 to $8 per share as analysts factor in updated Q4 results, a shift in GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research on Stevanato Group reflects a mix of reduced price targets and generally supportive views on the company’s execution in biologics, premium formats, and GLP-1 related revenue.Narrativ-Update • Mar 11
STVN: Biologics Mix Shift And On Body Delivery Partnership Will Support Future Cash Flows
Analysts have trimmed their consolidated price target on Stevanato Group by $4.09 to $32.00. This reflects updated models after Q4 results, slightly lower fair value assumptions, modestly higher discount rates, and more measured expectations for revenue growth, profit margins, and future P/E, even as they continue to highlight strength in GLP-1 and broader biologics demand.Narrativ-Update • Feb 25
STVN: Large-Volume Self-Administration Partnership Will Support Future Upside Potential
Analysts have trimmed their 12 month price target on Stevanato Group by about $4.90 per share to reflect updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E multiples, citing recent Street research calls that include Jefferies cutting its target by $5.50. Analyst Commentary Bearish analysts are signaling a more cautious stance on Stevanato Group, reflected in reduced 12 month price targets that factor in updated views on fair value, discount rates, revenue growth, profit margins, and future P/E multiples.Narrativ-Update • Feb 09
STVN: Large Volume On-Body Delivery Partnership Will Support Stronger Future Cash Flows
Analysts have nudged their fair value estimate for Stevanato Group slightly higher to US$36.09, citing small adjustments to discount rate assumptions, revenue growth outlook, profit margin expectations, and a refined future P/E framework. What's in the News Datwyler, LTS Device Technologies and Stevanato Group entered a collaboration focused on large volume subcutaneous drug delivery using on-body administration for larger dose volumes (Key Developments).Analyseartikel • Feb 04
Why We're Not Concerned Yet About Stevanato Group S.p.A.'s (NYSE:STVN) 27% Share Price Plunge
Unfortunately for some shareholders, the Stevanato Group S.p.A. ( NYSE:STVN ) share price has dived 27% in the last...Narrativ-Update • Jan 26
STVN: Large Volume Drug Delivery Collaboration Will Support Stronger Future Cash Flows
Analysts have nudged their price target for Stevanato Group slightly higher to $36.08 from $36.05, citing updated assumptions for revenue growth, profit margins, and future P/E that modestly adjust their long term valuation. What's in the News Datwyler, LTS Device Technologies and Stevanato Group announced a collaboration focused on large volume subcutaneous drug delivery, targeting more convenient on body administration of larger doses for patients, with a joint platform to be presented at Pharmapack in Paris on January 21 to 22, 2026 (Key Developments).Narrativ-Update • Jan 11
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts now estimate Stevanato Group's fair value price target at approximately US$36.05, a very small adjustment from about US$36.08. This reflects updated views that combine slightly higher revenue growth expectations with modestly lower profit margin assumptions and a marginally higher future P/E outlook.Analyseartikel • Jan 06
Are Stevanato Group S.p.A. (NYSE:STVN) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stevanato Group fair value estimate is US$16.36 Current share...Seeking Alpha • Jan 03
Stevanato: Structural Growth Intact, Buy Confirmed
Summary Stevanato's biologics remain the core growth engine supported by a broad pipeline, resilient GLP-1 demand, vial recovery, and a favorable industry backdrop. While Engineering continues to weigh on margins in the short run, the weakness appears cyclical rather than structural, with optimization progressing and limited impact on group fundamentals. After a ~14% pullback, long-term earnings visibility remains strong, supporting higher 2026 profitability assumptions and a higher target price, leading us to maintain a constructive stance. Read the full article on Seeking AlphaNarrativ-Update • Dec 27
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts have nudged their price target on Stevanato Group slightly higher to approximately $36.08 per share from about $36.05, citing modestly stronger expectations for revenue growth and profit margins that more than offset a small anticipated decline in the company’s future price to earnings multiple. What's in the News Maintained 2025 revenue guidance, expecting between €1.160 billion and €1.190 billion, signaling confidence in demand and operational execution (Corporate Guidance) Announced a significant expansion of drug delivery system manufacturing capacity in Bad Oeynhausen, Germany, adding over 2,500 square meters of advanced production space to support global pharma and biotech customers (Business Expansions) Invested multi millions in an ISO 8 cleanroom environment equipped for injection molding and automated assembly, aimed at strengthening resilient, Europe based supply chains for partners (Business Expansions) Enhanced the Bad Oeynhausen site to scale production of key devices such as the Aidaptus autoinjector and Alina pen injector platforms, reinforcing the company’s role in patient centric combination products (Business Expansions) Valuation Changes Fair Value Estimate has risen slightly to approximately $36.08 per share from about $36.05.Narrativ-Update • Dec 12
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Profit Margins
Analysts have modestly trimmed their price target on Stevanato Group to approximately $36.05 from about $36.07, reflecting slightly higher perceived risk via a raised discount rate, which is only partly offset by improved profit margin expectations and a marginally lower forecast valuation multiple. What's in the News Maintained 2025 revenue guidance, with expected revenue in the range of €1.160 billion to €1.190 billion (Corporate guidance) Announced a significant expansion of drug delivery system manufacturing capacity at its Bad Oeynhausen, Germany facility, adding over 2,500 square meters of advanced production space (Business expansion) Invested multiple millions in a new ISO 8 cleanroom, injection molding, and automated assembly operations to support global pharma and biotech partners with resilient European supply chains (Business expansion) Strengthened production capabilities for key platforms, including the Aidaptus autoinjector and Alina pen injector, enhancing its role in patient centric combination products (Business expansion) Valuation Changes Fair Value Estimate: edged down slightly to approximately €36.05 from about €36.07 per share, reflecting a marginally lower intrinsic valuation.Narrativ-Update • Nov 25
STVN: German Facility Expansion Will Drive Stronger Supply Chain Integration
Analysts have slightly lowered their price target for Stevanato Group, adjusting the fair value from $28.80 to $28.78 based on minor updates to growth and profitability expectations. What's in the News Stevanato Group S.p.A. maintained its revenue guidance for 2025, expecting revenues in the range of €1.160 billion to €1.190 billion (Key Developments).Narrativ-Update • Nov 11
STVN: Expansion Of German Manufacturing Facility Will Fuel Future Upside
Narrative Update on Stevanato Group Price Target Analysts have raised their price target for Stevanato Group slightly, increasing it from $28.62 to $28.80. This change is attributed to modest improvements in projected revenue growth and profit margins, despite a higher discount rate.Analyseartikel • Sep 22
Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings
Stevanato Group S.p.A.'s ( NYSE:STVN ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong...Analyseartikel • Aug 08
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
NYSE:STVN 1 Year Share Price vs Fair Value Explore Stevanato Group's Fair Values from the Community and select yours A...Analyseartikel • Jun 23
Stevanato Group (NYSE:STVN) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Mar 09
Stevanato: Ramping Syringe Demand, Buy Confirmed
Summary Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides downside protection in case of tariff war. Stevanato's valuation is supported by sales accelleration and EBITDA growth evolution. Read the full article on Seeking Alpha
Neues Narrativ • Nov 20
Engineering Optimization And Capacity Expansion To Unlock Growth Opportunities
Optimizing the Engineering segment and strategic shifts towards ready-to-use systems are expected to drive cost savings, improve margins, and boost productivity.Seeking Alpha • Nov 13
Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Summary Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rating target. Read the full article on Seeking AlphaSeeking Alpha • May 29
Stevanato: Destock Pressures, Long-Term Upside
Summary Stevanato revised its guidance for 2024 due to weaker-than-expected orders and clients' destocking activities. The company's Q1 results show decreased EBITDA and profit, causing investors to sell off shares. Here at the Lab, we remain confident in long-term prospects thanks to capacity expansion and biologics demand. STVN is not trading at a premium compared to its peers. Therefore, we reinstated a buy rating status. Read the full article on Seeking AlphaSeeking Alpha • Mar 12
Stevanato: Destocking And Valuation Risk (Rating Downgrade)
Summary Stevanato's peers decided to lower sales growth estimates in 2024 due to clients' destocking activities. The company's EBITDA and net profit declined due to start-up costs and an unfavorable exchange rate effect. Stevanato's valuation looks full compared to its peers. We move our rating to neutral. Read the full article on Seeking AlphaGeschäftsführer
Franco Stevanato (52 yo)
1.9yrs
Amtszeit
Mr. Franco Stevanato has been Executive Chairman of the Board at Stevanato Group S.p.A. since February 18, 2021, and serves as its Chief Executive Officer since June 30, 2024. He was Chief Executive Office...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Executive Chairman | 1.9yrs | keine Daten | keine Daten | |
| Chief Financial Officer | no data | keine Daten | 0.027% $ 1.4m | |
| Chief Communications & Investor Relations Officer | no data | keine Daten | keine Daten | |
| Chief Human Resources Officer | 1.1yrs | keine Daten | keine Daten | |
| Chief Business Officer | 7.3yrs | keine Daten | 0.15% $ 7.3m | |
| President of DDS & IVD Business Unit | less than a year | keine Daten | keine Daten | |
| President of Engineering Business Unit | 1.3yrs | keine Daten | keine Daten |
1.3yrs
Durchschnittliche Betriebszugehörigkeit
52yo
Durchschnittliches Alter
Erfahrenes Management: STVNDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Executive Chairman | 5.3yrs | keine Daten | keine Daten | |
| Lead Independent Director | 13.3yrs | keine Daten | 0.044% $ 2.2m | |
| Independent Director | 8.3yrs | keine Daten | 0.012% $ 611.2k | |
| Independent Director | 5yrs | keine Daten | 0.019% $ 951.4k | |
| Independent Director | 1yr | keine Daten | keine Daten | |
| Independent Director | 8.3yrs | keine Daten | 0.024% $ 1.2m | |
| Independent Director | 2yrs | keine Daten | 0.00065% $ 32.0k | |
| Independent Director | 2yrs | keine Daten | 0.00083% $ 40.8k | |
| Emeritus Chairman | no data | keine Daten | keine Daten | |
| Independent Director | 1yr | keine Daten | 0.00073% $ 35.9k | |
| Director | 15.3yrs | keine Daten | 0.0012% $ 59.5k |
5.1yrs
Durchschnittliche Betriebszugehörigkeit
67yo
Durchschnittliches Alter
Erfahrener Vorstand: STVNDie Vorstandsmitglieder gelten als erfahren (5.1 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/24 13:22 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Stevanato Group S.p.A. wird von 17 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Hugo Solvet | BNP Paribas |
| Curtis Moiles | BNP Paribas |
| Michael Ryskin | BofA Global Research |